57 completed, 25 recruiting, 22 terminated, 21 active not recruiting. 90 Phase 2, 51 Phase 1, 14 Phase 3, 4 Phase 4, 2 Not applicable.
Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer Ipilimumab N01, Sintilimab, Cetuximab - BRAF V600E, Colorectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 49 | 2026-03-01 | 2026-04-07 |
| Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor - Thyroid Cancer, Thyroid Neoplasms | Recruiting | Fujian Medical University | 120 | 2025-12-23 | 2026-02-19 | |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Recruiting | University of California, San Francisco | 96 | 2025-11-07 | 2026-10-26 |
| MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. Dabrafenib + Trametinib, Pembrolizumab, Nivolumab - Melanoma, Fertility | Recruiting | Intergruppo Melanoma Italiano | 270 | 2025-08-04 | 2025-09-05 | |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Recruiting | West China Second University Hospital | 20 | 2025-06-01 | 2025-06-15 |
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma | Phase 1 / Phase 2 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 27 | 2025-04-01 | 2026-07-10 |
| Precision Cancer Therapy in Rare Cancers Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm | Phase 2 | Recruiting | Oslo University Hospital | 96 | 2025-03-20 | 2025-03-26 |
| A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms | Phase 2 | Recruiting | Blokhin's Russian Cancer Research Center | 64 | 2025-03-01 | 2025-05-18 |
| Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma Dabrafenib and trametinib (combination) - Ameloblastoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 46 | 2025-03-01 | 2025-02-11 |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer Biospecimen Collection, Cabozantinib, Computed Tomography - Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 264 | 2024-12-27 | 2026-09-24 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion Olaparib tablet, Temozolomide capsule, Anlotinib - Solid Tumor, Precision Medicine | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 300 | 2024-11-01 | 2024-12-18 |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Dabrafenib + Trametinib - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Saint Petersburg State University, Russia | 10 | 2024-03-25 | 2024-04-12 |
| Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma Dabrafenib - Ameloblastoma | Phase 3 | Unknown | Shandong University | 10 | 2024-03-01 | 2024-02-20 |
| Special Drug Use-results Surveillance of Tafinlar/Mekinist Tafinlar/Mekinist - BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor | Recruiting | Novartis Pharmaceuticals | 110 | 2024-02-09 | 2026-06-17 | |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2024-02-01 | 2023-10-10 |
| Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib Combind asprin with Trametinib and Dabrafenib - NSCLC, BRAF V600E Mutation | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 36 | 2023-11-01 | 2023-10-12 |
Showing 20 of 158. Sign in to see all of them.
Melanoma (76) · Neoplasms (30) · Thyroid Neoplasms (12) · Neoplasm Metastasis (11) · Carcinoma, Non-Small-Cell Lung (10) · Thyroid Carcinoma, Anaplastic (10) · Brain Neoplasms (9) · Glioma (9) · Colorectal Neoplasms (7) · Hematologic Neoplasms (7) · Multiple Myeloma (7) · Skin Neoplasms (6) · Ameloblastoma (4) · Histiocytosis, Langerhans-Cell (4) · Thyroid Cancer, Papillary (4)
Novartis Pharmaceuticals (31) · GlaxoSmithKline (17) · National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (5) · Massachusetts General Hospital (5) · Memorial Sloan Kettering Cancer Center (4) · Universitair Ziekenhuis Brussel (3) · Cancer Research UK (2) · ECOG-ACRIN Cancer Research Group (2) · Fujian Medical University (2) · Melanoma Institute Australia (2) · Oslo University Hospital (2) · Saint Petersburg State University, Russia (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · The Netherlands Cancer Institute (2)
United States (88) · Australia (27) · France (25) · Canada (20) · Germany (20) · Italy (20) · United Kingdom (19) · Spain (17) · China (15) · Netherlands (15) · Russia (13) · Belgium (12) · Japan (12) · Argentina (9) · Denmark (9)
Rodabe N Amaria (2) · Ryan J Sullivan (2) · Ahmad Awada, PhD (1) · Alain Algazi, MD (1) · Alain P Algazi (1) · Alan L Ho, MD, PhD (1) · Alexander Colevas (1) · Andrew M Scott, MD, FRACP (1) · Anne Hansen Ree, Prof. MD PhD (1) · Antoine Italiano (1) · Antoni Ribas (1) · Arjun Sahgal (1) · Arthur Frankel, MD (1)
PMID 24408395, PMID 34225229, PMID 26446943, PMID 27864013, PMID 34331515, PMID 36884302, PMID 23645591, PMID 31166680, PMID 31864178, PMID 33587894, PMID 36648215, PMID 37219859, PMID 37934000, PMID 15049016, PMID 18623218, PMID 19731321, PMID 23255383, PMID 23589673, PMID 24577748, PMID 24769640, PMID 24983357, PMID 25092772, PMID 25265492, PMID 25287827, PMID 25399551, PMID 25411413, PMID 25549723, PMID 25794603, PMID 25797743, PMID 26037941, PMID 26040620, PMID 26194764, PMID 26340744, PMID 26392102, PMID 26433819, PMID 26586415, PMID 26811525, PMID 27080216, PMID 27124486, PMID 27223498, PMID 27283860, PMID 28268064, PMID 28592387, PMID 28879519, PMID 28891408, PMID 28919011, PMID 28991513, PMID 29072975, PMID 29243287, PMID 29263218
U10CA180820 (5), U01CA062490 (4), UM1CA186709 (4), 2016 (3), 2023 (3), 2015 (2), 2017 (2), P30CA006516 (2), U10CA032102 (2), U10CA180888 (2), U24CA196172 (2), UM1CA186716 (2), 2018 (1), 2019 (1), P30CA008748 (1)